“…Twenty-five of the 63 included studies (39.7%) involved predominately high-risk cohorts. 15,26,28,29,31,35,37,39,41,42,45,51,54,56,57,59,60,62,65,67,71,[73][74][75]78 Six inclusions (9.5%) were validation studies assessing novel cfDNA technologies or algorithms. 15,29,31,39,47,49 Seventeen studies (27.0%) reported cfDNA screening outcomes for 22q.11.2 syndrome (16 reporting PPV 12,14,26,27,30,38,40,47,56,60,65,68,69,73,76,83 and three reporting sensitivity and specificity 39,60,76 ), inc...…”